View Future GrowthSwedencare 過去の業績過去 基準チェック /16Swedencareは、平均年間3.2%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間10.7% 26%収益成長率で 成長しています。 Swedencareの自己資本利益率は0.7%であり、純利益率は1.8%です。主要情報3.19%収益成長率-4.15%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率26.02%株主資本利益率0.71%ネット・マージン1.83%次回の業績アップデート22 Jul 2026最近の業績更新お知らせ • Dec 10+ 2 more updatesSwedencare AB (publ) to Report Q2, 2026 Results on Jul 22, 2026Swedencare AB (publ) announced that they will report Q2, 2026 results on Jul 22, 2026お知らせ • Nov 09Swedencare AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Apr 02, 2026お知らせ • May 17Swedencare AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Swedencare AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Mar 22Swedencare AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Feb 12, 2026お知らせ • Mar 13Swedencare AB (publ) to Report Fiscal Year 2024 Results on Apr 03, 2025Swedencare AB (publ) announced that they will report fiscal year 2024 results on Apr 03, 2025お知らせ • Jan 22Swedencare AB (publ) to Report Q3, 2025 Results on Oct 22, 2025Swedencare AB (publ) announced that they will report Q3, 2025 results on Oct 22, 2025すべての更新を表示Recent updatesお知らせ • Apr 23Swedencare AB (Publ) Approves Board ChangesSwedencare AB (publ) at its Annual General Meeting held on April 23, 2026, elected Diego Maurizio and Thomas Thomsen as board members. The Annual General Meeting decided to new elect Thomas Eklund as Chairman of the Board.お知らせ • Mar 26Swedencare Showcases Proden Plaqueoff Crunchy Dental Bites At Global Pet ExpoSwedencare was at Global Pet Expo in Orlando, Florida, from March 25 to 27 in booth #4401 showcasing ProDen PlaqueOff Crunchy Dental Bites. These bite-sized supplements help reduce plaque and tartar buildup while keeping breath fresh, all in a tasty, pet-approved format. Formulated with the brand's signature A.N ProDen (a 100% organic kelp sustainably harvested from pristine Scandinavian waters), these bites offer a simple and tasty way to support a healthier smile. ProDen PlaqueOff is formulated to work naturally without the need for chewing or brushing, supporting the prevention of plaque buildup and the softening of tartar. With no artificial additives, preservatives or flavors, pet parents can confidently give their pets a cleaner, healthier mouth without any unnecessary fillers. These supplements come in a tasty veggie flavor and are available in three convenient sizes: a six-ounce bag for medium and large dogs, a three-ounce bag for small dogs, and a three-ounce bag for cats. Easy to incorporate into any routine, these low-calorie bites can be given daily alongside a pet's regular dental care regimen. Plus, the dog formula is VOHC-approved for both plaque and tartar control, providing pet parents with a trusted, research-backed solution for long-term oral health.お知らせ • Mar 25Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.2800 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.お知らせ • Feb 13Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.3500 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.お知らせ • Dec 10+ 2 more updatesSwedencare AB (publ) to Report Q2, 2026 Results on Jul 22, 2026Swedencare AB (publ) announced that they will report Q2, 2026 results on Jul 22, 2026お知らせ • Nov 09Swedencare AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Apr 02, 2026お知らせ • Oct 31Swedencare AB (publ), Annual General Meeting, Feb 26, 2026Swedencare AB (publ), Annual General Meeting, Feb 26, 2026.お知らせ • May 17Swedencare AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Swedencare AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Apr 24+ 1 more updateSwedencare AB (Publ) Approves Election of Isabelle Guiller as DirectorSwedencare AB (publ) announced that at its AGM held on April 25, 2025, shareholders approved the election of Isabelle Guiller as director.お知らせ • Mar 24Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million.Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million on March 24, 2025. Under the terms of agreement, the initial purchase price is £30 million (approximately SEK 395.4 million) along with a two-year earn-out arrangement. The cash consideration will include £27 million (approximately SEK 355.9 million) drawn from available cash and RCF-credit) and an issue-in-kind of 978,119 shares in Swedencare (approximately SEK 39.5 million) to the seller upon closing, which is expected to take place on April 1, 2025. A condition-based purchase price (earn-out) of a maximum GBP 15 million (SEK 197.7 million) may be paid if certain conditions are met as of April 1, 2027. For the calendar year 2024, Summit Veterinary Pharmaceuticals Limited had revenue of £2.7 million. Post completion of the acquiistion, Summit will continue to be led by Steve Organ, the founder and former owner, for the next two years. Steve will also become a shareholder of Swedencare with 978,119 shares. Advokatfirman Lindahl KB, with the assistance of Reynolds Porter Chamberlain LLP (RPC) acted as legal advisor to Swedencare. Lincoln International acted as exclusive financial advisor to Summit UK for the transaction. Redfern acted as exclusive legal advisor to Summit UK for the transaction. Swedencare AB (publ) (OM:SECARE) completed the acquisition of Summit Veterinary Pharmaceuticals Limited on March 24, 2025.お知らせ • Mar 22Swedencare AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Feb 12, 2026お知らせ • Mar 13Swedencare AB (publ) to Report Fiscal Year 2024 Results on Apr 03, 2025Swedencare AB (publ) announced that they will report fiscal year 2024 results on Apr 03, 2025お知らせ • Jan 22Swedencare AB (publ) to Report Q3, 2025 Results on Oct 22, 2025Swedencare AB (publ) announced that they will report Q3, 2025 results on Oct 22, 2025お知らせ • Nov 20Swedencare AB (publ) to Report Q4, 2024 Results on Mar 11, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results at 9:00 AM, Central European Standard Time on Mar 11, 2025お知らせ • Nov 15Swedencare AB (publ), Annual General Meeting, Apr 24, 2025Swedencare AB (publ), Annual General Meeting, Apr 24, 2025.お知らせ • Aug 23+ 1 more updateSwedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025Swedencare AB (publ) announced that they will report Q2, 2025 results on Jul 24, 2025お知らせ • Apr 26+ 2 more updatesSwedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results on Feb 13, 2025お知らせ • Nov 17Swedencare AB (Publ) Announces Nomination Committee AppointmentsSwedencare AB (publ) appointed a nomination committee for the Annual General Meeting on April 25th, 2024. The Nomination Committee consists of the following persons: Håkan Svanberg, appointed by Håkan Svanberg & Co Health Care AB, Chairman of the Nomination Committee, Heinz-Juergen Bertram, appointed by Symrise AG, Anna Magnusson, appointed by Första AP-fonden.お知らせ • Oct 26+ 3 more updatesSwedencare AB (publ), Annual General Meeting, Apr 25, 2024Swedencare AB (publ), Annual General Meeting, Apr 25, 2024.お知らせ • Jun 07Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billionSymrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion on June 5, 2023. Under the terms, SEK 37.50 per share in cash will be acquired for 111,112,282 shares. The consideration payable in respect of the Offer is financed in full by available funds and existing credit facilities. Completion of the Offer is conditional upon the Offer and the acquisition of Swedencare receiving all necessary regulatory, governmental or similar clearances, approvals and decisions, including approvals and clearances, competition authorities and Swedencare's board approval. The acceptance period for the Offer commences on June 21, 2023 and expires on July 26, 2023. Skandinaviska Enskilda Banken AB acted as financial advisor and Advokatfirman Vinge as legal advisor to Symrise AG.お知らせ • Feb 17+ 1 more updateSwedencare AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 final results on Apr 06, 2023お知らせ • Feb 16+ 1 more updateSwedencare AB (publ) to Report First Half, 2023 Results on Jul 27, 2023Swedencare AB (publ) announced that they will report first half, 2023 results on Jul 27, 2023お知らせ • Feb 11Swedencare AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023収支内訳Swedencare の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:SWDC.F 収益、費用、利益 ( )SEK Millions日付収益収益G+A経費研究開発費31 Mar 262,700491,066031 Dec 252,691561,053030 Sep 252,675631,031030 Jun 252,603651,000031 Mar 252,58293955031 Dec 242,53699912030 Sep 242,50462898030 Jun 242,47276859031 Mar 242,41472830031 Dec 232,33859803030 Sep 232,20887750030 Jun 232,08553726031 Mar 231,98797690031 Dec 221,84395640030 Sep 221,60098547030 Jun 221,335105456031 Mar 221,01960345031 Dec 2177355259030 Sep 2161840205030 Jun 2146544146031 Mar 2133734114031 Dec 202403387030 Sep 201743472030 Jun 201362861031 Mar 201343058031 Dec 191273054030 Sep 191213050030 Jun 191132848031 Mar 191082747031 Dec 18992344030 Sep 18942341030 Jun 18922042031 Mar 18851741031 Dec 17861740030 Sep 17781239030 Jun 17701135031 Mar 17631231031 Dec 16541028030 Sep 1643923030 Jun 1637819031 Mar 1634815031 Dec 15277100質の高い収益: SWDC.FにはSEK71.6M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。利益率の向上: SWDC.Fの現在の純利益率 (1.8%)は、昨年(3.6%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SWDC.Fの収益は過去 5 年間で年間3.2%増加しました。成長の加速: SWDC.Fは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: SWDC.Fは過去 1 年間で収益成長率がマイナス ( -46.8% ) となったため、 Pharmaceuticals業界平均 ( -4.8% ) と比較することが困難です。株主資本利益率高いROE: SWDC.Fの 自己資本利益率 ( 0.7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 16:13終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Swedencare AB (publ) 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Johan BrownABG Sundal Collier SponsoredAdela DashianJefferies LLCAdrian ElmlundNordea Markets1 その他のアナリストを表示
お知らせ • Dec 10+ 2 more updatesSwedencare AB (publ) to Report Q2, 2026 Results on Jul 22, 2026Swedencare AB (publ) announced that they will report Q2, 2026 results on Jul 22, 2026
お知らせ • Nov 09Swedencare AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Apr 02, 2026
お知らせ • May 17Swedencare AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Swedencare AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Mar 22Swedencare AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Feb 12, 2026
お知らせ • Mar 13Swedencare AB (publ) to Report Fiscal Year 2024 Results on Apr 03, 2025Swedencare AB (publ) announced that they will report fiscal year 2024 results on Apr 03, 2025
お知らせ • Jan 22Swedencare AB (publ) to Report Q3, 2025 Results on Oct 22, 2025Swedencare AB (publ) announced that they will report Q3, 2025 results on Oct 22, 2025
お知らせ • Apr 23Swedencare AB (Publ) Approves Board ChangesSwedencare AB (publ) at its Annual General Meeting held on April 23, 2026, elected Diego Maurizio and Thomas Thomsen as board members. The Annual General Meeting decided to new elect Thomas Eklund as Chairman of the Board.
お知らせ • Mar 26Swedencare Showcases Proden Plaqueoff Crunchy Dental Bites At Global Pet ExpoSwedencare was at Global Pet Expo in Orlando, Florida, from March 25 to 27 in booth #4401 showcasing ProDen PlaqueOff Crunchy Dental Bites. These bite-sized supplements help reduce plaque and tartar buildup while keeping breath fresh, all in a tasty, pet-approved format. Formulated with the brand's signature A.N ProDen (a 100% organic kelp sustainably harvested from pristine Scandinavian waters), these bites offer a simple and tasty way to support a healthier smile. ProDen PlaqueOff is formulated to work naturally without the need for chewing or brushing, supporting the prevention of plaque buildup and the softening of tartar. With no artificial additives, preservatives or flavors, pet parents can confidently give their pets a cleaner, healthier mouth without any unnecessary fillers. These supplements come in a tasty veggie flavor and are available in three convenient sizes: a six-ounce bag for medium and large dogs, a three-ounce bag for small dogs, and a three-ounce bag for cats. Easy to incorporate into any routine, these low-calorie bites can be given daily alongside a pet's regular dental care regimen. Plus, the dog formula is VOHC-approved for both plaque and tartar control, providing pet parents with a trusted, research-backed solution for long-term oral health.
お知らせ • Mar 25Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.2800 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.
お知らせ • Feb 13Swedencare AB (publ) announces Annual dividend, payable on April 30, 2026Swedencare AB (publ) announced Annual dividend of SEK 0.3500 per share payable on April 30, 2026, ex-date on April 24, 2026 and record date on April 27, 2026.
お知らせ • Dec 10+ 2 more updatesSwedencare AB (publ) to Report Q2, 2026 Results on Jul 22, 2026Swedencare AB (publ) announced that they will report Q2, 2026 results on Jul 22, 2026
お知らせ • Nov 09Swedencare AB (publ) to Report Fiscal Year 2025 Results on Apr 02, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Apr 02, 2026
お知らせ • Oct 31Swedencare AB (publ), Annual General Meeting, Feb 26, 2026Swedencare AB (publ), Annual General Meeting, Feb 26, 2026.
お知らせ • May 17Swedencare AB (publ) to Report Q1, 2026 Results on Apr 23, 2026Swedencare AB (publ) announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Apr 24+ 1 more updateSwedencare AB (Publ) Approves Election of Isabelle Guiller as DirectorSwedencare AB (publ) announced that at its AGM held on April 25, 2025, shareholders approved the election of Isabelle Guiller as director.
お知らせ • Mar 24Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million.Swedencare AB (publ) (OM:SECARE) acquired Summit Veterinary Pharmaceuticals Limited for £44.8 million on March 24, 2025. Under the terms of agreement, the initial purchase price is £30 million (approximately SEK 395.4 million) along with a two-year earn-out arrangement. The cash consideration will include £27 million (approximately SEK 355.9 million) drawn from available cash and RCF-credit) and an issue-in-kind of 978,119 shares in Swedencare (approximately SEK 39.5 million) to the seller upon closing, which is expected to take place on April 1, 2025. A condition-based purchase price (earn-out) of a maximum GBP 15 million (SEK 197.7 million) may be paid if certain conditions are met as of April 1, 2027. For the calendar year 2024, Summit Veterinary Pharmaceuticals Limited had revenue of £2.7 million. Post completion of the acquiistion, Summit will continue to be led by Steve Organ, the founder and former owner, for the next two years. Steve will also become a shareholder of Swedencare with 978,119 shares. Advokatfirman Lindahl KB, with the assistance of Reynolds Porter Chamberlain LLP (RPC) acted as legal advisor to Swedencare. Lincoln International acted as exclusive financial advisor to Summit UK for the transaction. Redfern acted as exclusive legal advisor to Summit UK for the transaction. Swedencare AB (publ) (OM:SECARE) completed the acquisition of Summit Veterinary Pharmaceuticals Limited on March 24, 2025.
お知らせ • Mar 22Swedencare AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026Swedencare AB (publ) announced that they will report fiscal year 2025 results on Feb 12, 2026
お知らせ • Mar 13Swedencare AB (publ) to Report Fiscal Year 2024 Results on Apr 03, 2025Swedencare AB (publ) announced that they will report fiscal year 2024 results on Apr 03, 2025
お知らせ • Jan 22Swedencare AB (publ) to Report Q3, 2025 Results on Oct 22, 2025Swedencare AB (publ) announced that they will report Q3, 2025 results on Oct 22, 2025
お知らせ • Nov 20Swedencare AB (publ) to Report Q4, 2024 Results on Mar 11, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results at 9:00 AM, Central European Standard Time on Mar 11, 2025
お知らせ • Nov 15Swedencare AB (publ), Annual General Meeting, Apr 24, 2025Swedencare AB (publ), Annual General Meeting, Apr 24, 2025.
お知らせ • Aug 23+ 1 more updateSwedencare AB (publ) to Report Q2, 2025 Results on Jul 24, 2025Swedencare AB (publ) announced that they will report Q2, 2025 results on Jul 24, 2025
お知らせ • Apr 26+ 2 more updatesSwedencare AB (publ) to Report Q4, 2024 Results on Feb 13, 2025Swedencare AB (publ) announced that they will report Q4, 2024 results on Feb 13, 2025
お知らせ • Nov 17Swedencare AB (Publ) Announces Nomination Committee AppointmentsSwedencare AB (publ) appointed a nomination committee for the Annual General Meeting on April 25th, 2024. The Nomination Committee consists of the following persons: Håkan Svanberg, appointed by Håkan Svanberg & Co Health Care AB, Chairman of the Nomination Committee, Heinz-Juergen Bertram, appointed by Symrise AG, Anna Magnusson, appointed by Första AP-fonden.
お知らせ • Oct 26+ 3 more updatesSwedencare AB (publ), Annual General Meeting, Apr 25, 2024Swedencare AB (publ), Annual General Meeting, Apr 25, 2024.
お知らせ • Jun 07Symrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billionSymrise AG (XTRA:SY1) announces a mandatory public offer to acquire remaining 70% stake in Swedencare AB (publ) (OM:SECARE) for SEK 4.2 billion on June 5, 2023. Under the terms, SEK 37.50 per share in cash will be acquired for 111,112,282 shares. The consideration payable in respect of the Offer is financed in full by available funds and existing credit facilities. Completion of the Offer is conditional upon the Offer and the acquisition of Swedencare receiving all necessary regulatory, governmental or similar clearances, approvals and decisions, including approvals and clearances, competition authorities and Swedencare's board approval. The acceptance period for the Offer commences on June 21, 2023 and expires on July 26, 2023. Skandinaviska Enskilda Banken AB acted as financial advisor and Advokatfirman Vinge as legal advisor to Symrise AG.
お知らせ • Feb 17+ 1 more updateSwedencare AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 final results on Apr 06, 2023
お知らせ • Feb 16+ 1 more updateSwedencare AB (publ) to Report First Half, 2023 Results on Jul 27, 2023Swedencare AB (publ) announced that they will report first half, 2023 results on Jul 27, 2023
お知らせ • Feb 11Swedencare AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023Swedencare AB (publ) announced that they will report fiscal year 2022 results at 8:00 AM, Central European Standard Time on Feb 16, 2023